Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of ...

Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant ...

Immutep ( (IMMP)) has issued an announcement. On 22 December 2025, Immutep reported positive initial results from a placebo-controlled, double-blind first-in-human Phase I trial of IMP761, its ...

(RTTNews) - Eli Lilly and Company (LLY) announced updated results from the Phase 3 EMBER-3 study evaluating Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen ...

Anixa Biosciences ( (ANIX)) just unveiled an announcement. On December 11, 2025, Anixa Biosciences announced positive final data from its Phase 1 clinical trial of an investigational breast cancer ...

BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced positive ...

The MarketWatch News Department was not involved in the creation of this content. Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene ...

Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend ...

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or ...

53% response rate in PD-L1 negative patients, comparing favorably to historical response of 23-32% with standard of care chemoimmunotherapy 60% response rate in 10 patients with STK11, KEAP1, and/or ...

Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer 53% ...

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for ...